Eradication of established tumors by CD8+ T cell adoptive immunotherapy - PubMed

Eradication of established tumors by CD8+ T cell adoptive immunotherapy

H L Hanson et al. Immunity. 2000 Aug.

Free article

Abstract

We generated the DUC18 T cell receptor transgenic mouse expressing an H-2Kd -restricted transgenic T cell receptor specific for the syngeneic CMS5 fibrosarcoma rejection antigen mutated ERK2(136-144). DUC18 mice were capable of specifically eliminating lethal CMS5 tumor challenges, and transfer of DUC18 splenocytes to naive nontransgenic recipients conferred protection from subsequent and established CMS5 tumor burdens. Eradication of established tumor burdens by adoptive transfer of DUC18 splenocytes was dose and time dependent. Transferred tumor-specific T cells remained functional in vivo and capable of rejecting small tumors even in the presence of large, established tumor burdens. These findings highlight the kinetic battle between tumor growth and the production of a tumor-specific response and have critical implications for effective adoptive immunotherapy.

Similar articles

• CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.

  Hanson HL, Kang SS, Norian LA, Matsui K, O'Mara LA, Allen PM. Hanson HL, et al. J Immunol. 2004 Apr 1;172(7):4215-24. doi: 10.4049/jimmunol.172.7.4215. J Immunol. 2004. PMID: 15034034

• Successful elimination of large established tumors and avoidance of antigen-loss variants by aggressive adoptive T cell immunotherapy.

  Matsui K, O'Mara LA, Allen PM. Matsui K, et al. Int Immunol. 2003 Jul;15(7):797-805. doi: 10.1093/intimm/dxg078. Int Immunol. 2003. PMID: 12807818

• Stimulation through very late antigen-4 and -5 improves the multifunctionality and memory formation of CD8⁺ T cells.

  Hosoi H, Ikeda H, Imai N, Amaike C, Wang L, Orito Y, Yamane M, Ueno H, Ideno M, Nukaya I, Enoki T, Mineno J, Takesako K, Hirano S, Shiku H. Hosoi H, et al. Eur J Immunol. 2014 Jun;44(6):1747-58. doi: 10.1002/eji.201343969. Epub 2014 May 11. Eur J Immunol. 2014. PMID: 24723437

• CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors.

  Tatum AM, Mylin LM, Bender SJ, Fischer MA, Vigliotti BA, Tevethia MJ, Tevethia SS, Schell TD. Tatum AM, et al. J Immunol. 2008 Sep 15;181(6):4406-17. doi: 10.4049/jimmunol.181.6.4406. J Immunol. 2008. PMID: 18768900 Free PMC article.

• Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials.

  DiGiusto D, Cooper L. DiGiusto D, et al. Cytotherapy. 2007;9(7):613-29. doi: 10.1080/14653240701650320. Cytotherapy. 2007. PMID: 17943498 Free PMC article. Review.

Cited by

• Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors.

  Jahan F, Koski J, Schenkwein D, Ylä-Herttuala S, Göös H, Huuskonen S, Varjosalo M, Maliniemi P, Leitner J, Steinberger P, Bühring HJ, Vettenranta K, Korhonen M. Jahan F, et al. Front Mol Med. 2023 Feb 22;3:1070384. doi: 10.3389/fmmed.2023.1070384. eCollection 2023. Front Mol Med. 2023. PMID: 39086686 Free PMC article.

• Effect of systemic injection of heterogenous and homogenous opioids on peripheral cellular immune response in rats with bone cancer pain: A comparative study.

  Du JY, Liang Y, Fang JF, Jiang YL, Shao XM, He XF, Fang JQ. Du JY, et al. Exp Ther Med. 2016 Oct;12(4):2568-2576. doi: 10.3892/etm.2016.3647. Epub 2016 Sep 1. Exp Ther Med. 2016. PMID: 27703511 Free PMC article.

• Cancer immunotherapy: moving beyond current vaccines.

  Rosenberg SA, Yang JC, Restifo NP. Rosenberg SA, et al. Nat Med. 2004 Sep;10(9):909-15. doi: 10.1038/nm1100. Nat Med. 2004. PMID: 15340416 Free PMC article.

• Optimum in vitro expansion of human antigen-specific CD8 T cells for adoptive transfer therapy.

  Montes M, Rufer N, Appay V, Reynard S, Pittet MJ, Speiser DE, Guillaume P, Cerottini JC, Romero P, Leyvraz S. Montes M, et al. Clin Exp Immunol. 2005 Nov;142(2):292-302. doi: 10.1111/j.1365-2249.2005.02914.x. Clin Exp Immunol. 2005. PMID: 16232216 Free PMC article.

• A2A adenosine receptor protects tumors from antitumor T cells.

  Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. Ohta A, et al. Proc Natl Acad Sci U S A. 2006 Aug 29;103(35):13132-7. doi: 10.1073/pnas.0605251103. Epub 2006 Aug 17. Proc Natl Acad Sci U S A. 2006. PMID: 16916931 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal